Skip to main content

Daruwala Paul's Form 4 filing

Cidara Therapeutics, Inc. (CDTX) · filed Jan 7, 2022

Accession no.
0001209191-22-002604
Filed
Jan 7, 2022
Trade date
Dec 29, 2021-Jan 5, 2022
Filing delay
9 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.42K. It was filed 9 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Daruwala PaulCIK 0001639144Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 29, 2021Common StockMOption exerciseAcquired+9,900$0.00$0192,431Direct
Jan 5, 2022Common StockSSaleDisposed−5,133$1.25−$6,416.25187,298Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 29, 2021Common StockMOption exerciseDisposed−5,000$0.00$012,500Direct
Dec 29, 2021Common StockMOption exerciseDisposed−4,900$0.00$05,600Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)